Shares of Aratana Therapeutics, Inc. (NASDAQ:PETX) gapped down before the market opened on Wednesday . The stock had previously closed at $7.74, but opened at $7.23. Aratana Therapeutics shares last traded at $5.86, with a volume of 2497600 shares trading hands.

Several analysts recently issued reports on PETX shares. HC Wainwright started coverage on Aratana Therapeutics in a research note on Friday, November 17th. They set a “buy” rating and a $10.00 target price on the stock. Jefferies Group reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Aratana Therapeutics in a research note on Friday, November 3rd. Zacks Investment Research raised Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 target price on the stock in a research report on Thursday, November 9th. Lake Street Capital cut their target price on Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 25th. Finally, BidaskClub downgraded Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 8th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. Aratana Therapeutics currently has a consensus rating of “Hold” and an average target price of $8.75.

The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.08 and a current ratio of 3.42.

Aratana Therapeutics (NASDAQ:PETX) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.03. The business had revenue of $6.16 million during the quarter, compared to analysts’ expectations of $6.47 million. Aratana Therapeutics had a negative return on equity of 48.79% and a negative net margin of 358.55%. The business’s revenue for the quarter was up 1440.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.38) EPS. sell-side analysts expect that Aratana Therapeutics, Inc. will post -1.03 EPS for the current fiscal year.

In other news, insider Peter Steven St sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $7.00, for a total transaction of $350,000.00. Following the sale, the insider now owns 529,359 shares of the company’s stock, valued at approximately $3,705,513. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Brent Standridge sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $6.11, for a total value of $61,100.00. Following the sale, the chief operating officer now directly owns 70,267 shares in the company, valued at approximately $429,331.37. The disclosure for this sale can be found here. Insiders sold 120,000 shares of company stock valued at $785,600 over the last ninety days. Insiders own 5.20% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. American International Group Inc. increased its position in shares of Aratana Therapeutics by 7.1% during the first quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,354 shares during the period. Janney Montgomery Scott LLC increased its position in shares of Aratana Therapeutics by 7.9% in the second quarter. Janney Montgomery Scott LLC now owns 16,400 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 1,200 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in shares of Aratana Therapeutics by 17.9% during the first quarter. Metropolitan Life Insurance Co. NY now owns 25,619 shares of the biopharmaceutical company’s stock valued at $136,000 after purchasing an additional 3,883 shares during the period. Voya Investment Management LLC boosted its stake in shares of Aratana Therapeutics by 22.7% during the second quarter. Voya Investment Management LLC now owns 19,530 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 3,610 shares during the period. Finally, Ray Gerald L & Associates Ltd. lifted its stake in Aratana Therapeutics by 0.8% in the second quarter. Ray Gerald L & Associates Ltd. now owns 24,100 shares of the biopharmaceutical company’s stock worth $174,000 after acquiring an additional 200 shares during the period. 73.95% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/01/aratana-therapeutics-petx-shares-gap-down-to-7-23.html.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Receive News & Stock Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related stocks with our FREE daily email newsletter.